Basic Stats
| CIK | 1616212 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Trillium Therapeutics Inc
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36596 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified i |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Trillium Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Add |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of i |
|
| November 17, 2021 |
As filed with the Securities and Exchange Commission on November 17, 2021 As filed with the Securities and Exchange Commission on November 17, 2021 Registration No. |
|
| November 17, 2021 |
As filed with the Securities and Exchange Commission on November 17, 2021 As filed with the Securities and Exchange Commission on November 17, 2021 Registration No. |
|
| November 17, 2021 |
Exhibit 99.1 For Immediate Release November 17, 2021 Media Contact: ????????????+1 (212) 733-1226 [email protected] Investor Contact:?????????+1 (212) 733-4848 [email protected] Pfizer Completes Acquisition of Trillium Therapeutics Acquisition enhances Pfizer?s Oncology portfolio with addition of next-generation, investigational immuno-therapeutics for hematological malignancies New York |
|
| November 17, 2021 |
As filed with the Securities and Exchange Commission on November 17, 2021 As filed with the Securities and Exchange Commission on November 17, 2021 Registration No. |
|
| November 17, 2021 |
As filed with the Securities and Exchange Commission on November 17, 2021 As filed with the Securities and Exchange Commission on November 17, 2021 Registration No. |
|
| November 17, 2021 |
As filed with the Securities and Exchange Commission on November 17, 2021 As filed with the Securities and Exchange Commission on November 17, 2021 Registration No. |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of i |
|
| November 15, 2021 |
TRIL / Trillium Therapeutics Inc. / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TRILLIUM THERAPEUTICS INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) November 15, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 12, 2021 |
Change in Control Severance Policy, effective as of August 20, 2021 ? Exhibit 10.1 Trillium Therapeutics Inc. U.S. Employee Change in Control Severance Policy Trillium Therapeutics Inc. hereby adopts the Trillium Therapeutics Inc. Change in Control Severance Policy for eligible employees of the Company (the ?Policy?), effective as of [?] (the ?Effective Date?). The Policy is designed to attract and retain talent and to assure the present and future continuity, obj |
|
| October 29, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of in |
|
| October 29, 2021 |
Trillium Therapeutics Receives Final Court Order Approving Arrangement Exhibit 99.1 Trillium Therapeutics Receives Final Court Order Approving Arrangement CAMBRIDGE, MA, October 28, 2021 Trillium Therapeutics Inc. (?Trillium? or the ?Company?) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia appr |
|
| October 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of in |
|
| October 27, 2021 |
Trillium Securityholders Approve Acquisition by Pfizer Exhibit 99.1 Trillium Securityholders Approve Acquisition by Pfizer CAMBRIDGE, MA, October 26, 2021 / GlobeNewsWire / Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (?Trillium? or the ?Company?) today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (?PF Argentum?) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (?Pfizer?) at the special meetin |
|
| October 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of in |
|
| October 20, 2021 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a - 101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Us |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of in |
|
| October 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of in |
|
| October 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of in |
|
| October 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of in |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| September 27, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, For Use of the Commission Only (as permitted by Ru |
|
| September 13, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Trillium Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Add |
|
| August 23, 2021 |
DEFA14A 1 tm2125674d3defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Def |
|
| August 23, 2021 |
Exhibit 99.1 VOTING SUPPORT AGREEMENT THIS AGREEMENT is made as of the 20th day of August, 2021. BETWEEN: PF ARGENTUM ACQUISITION ULC, a corporation formed under the laws of the Province of British Columbia (the Purchaser) - and - l, [an individual resident at l/a l formed under the laws of l] (the Shareholder) WHEREAS: (A) The Purchaser proposes to acquire all of the issued and outstanding Common |
|
| August 23, 2021 |
Exhibit 99.2 For Immediate Release August 23, 2021 Pfizer to Acquire Trillium Therapeutics Inc. Proposed acquisition strengthens Pfizer?s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10: |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of inc |
|
| August 23, 2021 |
Exhibit 2.1 PFIZER INC. - and - PF ARGENTUM ACQUISITION ULC - and - TRILLIUM THERAPEUTICS INC. ARRANGEMENT AGREEMENT August 20, 2021 TABLE OF CONTENTS Article 1 INTERPRETATION 1 Section 1.1 Defined Terms 1 Section 1.2 Certain Rules of Interpretation. 17 Section 1.3 Schedules. 18 Article 2 THE ARRANGEMENT 18 Section 2.1 Arrangement. 18 Section 2.2 Corporation Approval 18 Section 2.3 Interim Order. |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 13, 2021 |
TRILLIUM THERAPEUTICS REPORTS SECOND QUARTER 2021 OPERATING AND FINANCIAL RESULTS Exhibit 99.1 ? ? FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL ? TRILLIUM THERAPEUTICS REPORTS SECOND QUARTER 2021 OPERATING AND FINANCIAL RESULTS CAMBRIDGE, MA, August 13, 2021 ? Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three and six mon |
|
| August 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of inc |
|
| June 30, 2021 |
8-K 1 tm2120889d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (Sta |
|
| June 30, 2021 |
TRILLIUM THERAPEUTICS APPOINTS CATHERINE MACKEY, PH.D., TO ITS BOARD OF DIRECTORS Exhibit 99.1 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS APPOINTS CATHERINE MACKEY, PH.D., TO ITS BOARD OF DIRECTORS CAMBRIDGE, MA, June 30, 2021 ? Trillium Therapeutics Inc. (?Trillium? or the ?Company?) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical |
|
| June 9, 2021 |
TRILLIUM ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS Exhibit 99.1 FOR IMMEDIATE RELEASE NASDAQ:TRIL TSX: TRIL TRILLIUM ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS CAMBRIDGE, MA, June 9, 2021 ? Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the ?Corporation?), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual Gener |
|
| June 9, 2021 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of incorp |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-36596 TRILLIUM THERAPEUTICS |
|
| May 7, 2021 |
Employment Agreement between Trillium Therapeutics Inc. and Benjamin Looker effective April 26, 2021 Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?), effective April 26, 2021 (?Effective Date?), is made between Trillium Therapeutics USA Inc., a Delaware corporation (?Employer? or the ?Company?), and Benjamin Looker, Esq. (?Employee?). Employee and the Company are sometimes referred to herein as the ?Parties? and individually as a ?Party.? RECITALS A. Employer is an immun |
|
| May 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of incorpo |
|
| May 7, 2021 |
TRILLIUM THERAPEUTICS REPORTS FIRST QUARTER 2021 OPERATING AND FINANCIAL RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS REPORTS FIRST QUARTER 2021 OPERATING AND FINANCIAL RESULTS CAMBRIDGE, MA, May 7, 2021 – Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, |
|
| April 30, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Conf |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 28, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS PROVIDES DATA UPDATE, ANNOUNCES PHASE 1B/2 PROGRAM PRIORITIES ACROSS HEMATOLOGIC MALIGNANCIES AND SOLID TUMORS, AND REPORTS GOVERNANCE CHANGES ? TTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including 3 new responses (1 Complete Response (CR) + |
|
| April 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of inco |
|
| April 28, 2021 |
Exhibit 99.2 R&D DAY OPENING A NEW CHAPTER IN TRILLIUM?S EVOLUTION April 28, 2021 2 FORWARD-LOOKING STATEMENTS SAFE HARBOR This presentation contains forward-looking statements within the meaning of applicable securities laws including the Private Securities Litigation Reform Act of 1995, as amended. All statements contained herein that are not clearly historical in nature are forward-looking, and |
|
| April 28, 2021 |
Exhibit 99.3 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1B STUDY OF TTI-622 IN COMBINATION WITH CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA CAMBRIDGE, MA, APRIL 28, 2021 ? Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatme |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of inco |
|
| April 23, 2021 |
FORM 52-109F2R CERTIFICATION OF REFILED INTERIM FILINGS Exhibit 99.12 FORM 52-109F2R CERTIFICATION OF REFILED INTERIM FILINGS This certificate is being filed on the same date that Trillium Therapeutics Inc. (the ?issuer?) has refiled interim financial statements for the three and nine months ended September 30, 2020. I, James Parsons, Chief Financial Officer of Trillium Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim fi |
|
| April 23, 2021 |
Exhibit 99.10 NOTICE TO READER As of June 30, 2020, the last business day of the second quarter of Trillium Therapeutics Inc. (the ?Company?), the Company determined that it no longer qualified as a ?foreign private issuer? as such term is defined in Rule 405 under the United States Securities Act of 1933, as amended. As a result, effective January 1, 2021, the Company has been required to comply |
|
| April 23, 2021 |
Exhibit 99.6 NOTICE TO READER As of June 30, 2020, the last business day of the second quarter of Trillium Therapeutics Inc. (the ?Company?), the Company determined that it no longer qualified as a ?foreign private issuer? as such term is defined in Rule 405 under the United States Securities Act of 1933, as amended. As a result, effective January 1, 2021, the Company has been required to comply w |
|
| April 23, 2021 |
FORM 52-109F2R CERTIFICATION OF REFILED INTERIM FILINGS Exhibit 99.4 FORM 52-109F2R CERTIFICATION OF REFILED INTERIM FILINGS This certificate is being filed on the same date that Trillium Therapeutics Inc. (the ?issuer?) has refiled interim financial statements for the three months ended March 31, 2020. I, James Parsons, Chief Financial Officer of Trillium Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial statem |
|
| April 23, 2021 |
FORM 52-109F2R CERTIFICATION OF REFILED INTERIM FILINGS Exhibit 99.3 FORM 52-109F2R CERTIFICATION OF REFILED INTERIM FILINGS This certificate is being filed on the same date that Trillium Therapeutics Inc. (the ?issuer?) has refiled interim financial statements for the three months ended March 31, 2020. I, Jan Skvarka, Chief Executive Officer of Trillium Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial statemen |
|
| April 23, 2021 |
FORM 52-109F2 CERTIFICATION OF REFILED INTERIM FILINGS Exhibit 99.11 FORM 52-109F2 CERTIFICATION OF REFILED INTERIM FILINGS This certificate is being filed on the same date that Trillium Therapeutics Inc. (the ?issuer?) has refiled interim financial statements for the three and nine months ended September 30, 2020. I, Jan Skvarka, Chief Executive Officer of Trillium Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim finan |
|
| April 23, 2021 |
Exhibit 99.2 NOTICE TO READER As of June 30, 2020, the last business day of the second quarter of Trillium Therapeutics Inc. (the ?Company?), the Company determined that it no longer qualified as a ?foreign private issuer? as such term is defined in Rule 405 under the United States Securities Act of 1933, as amended. As a result, effective January 1, 2021, the Company has been required to comply w |
|
| April 23, 2021 |
Exhibit 99.1 NOTICE TO READER As of June 30, 2020, the last business day of the second quarter of Trillium Therapeutics Inc. (the “Company”), the Company determined that it no longer qualified as a “foreign private issuer” as such term is defined in Rule 405 under the United States Securities Act of 1933, as amended. As a result, effective January 1, 2021, the Company has been required to comply w |
|
| April 23, 2021 |
FORM 52-109F2 CERTIFICATION OF REFILED INTERIM FILINGS Exhibit 99.7 FORM 52-109F2 CERTIFICATION OF REFILED INTERIM FILINGS This certificate is being filed on the same date that Trillium Therapeutics Inc. (the ?issuer?) has refiled interim financial statements for the three and six months ended June 30, 2020. I, Jan Skvarka, Chief Executive Officer of Trillium Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial st |
|
| April 23, 2021 |
FORM 52-109F2R CERTIFICATION OF REFILED INTERIM FILINGS Exhibit 99.8 FORM 52-109F2R CERTIFICATION OF REFILED INTERIM FILINGS This certificate is being filed on the same date that Trillium Therapeutics Inc. (the ?issuer?) has refiled interim financial statements for the three and six months ended June 30, 2020. I, James Parsons, Chief Financial Officer of Trillium Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial |
|
| April 23, 2021 |
Exhibit 99.9 NOTICE TO READER As of June 30, 2020, the last business day of the second quarter of Trillium Therapeutics Inc. (the ?Company?), the Company determined that it no longer qualified as a ?foreign private issuer? as such term is defined in Rule 405 under the United States Securities Act of 1933, as amended. As a result, effective January 1, 2021, the Company has been required to comply w |
|
| April 23, 2021 |
Exhibit 99.5 NOTICE TO READER As of June 30, 2020, the last business day of the second quarter of Trillium Therapeutics Inc. (the ?Company?), the Company determined that it no longer qualified as a ?foreign private issuer? as such term is defined in Rule 405 under the United States Securities Act of 1933, as amended. As a result, effective January 1, 2021, the Company has been required to comply w |
|
| April 22, 2021 |
TRILLIUM THERAPEUTICS TO HOST VIRTUAL R&D DAY FOR INVESTORS ON APRIL 28, 2021 Exhibit 99.1 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS TO HOST VIRTUAL R&D DAY FOR INVESTORS ON APRIL 28, 2021 CAMBRIDGE, MA, APRIL 22, 2021 ? Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host its virtual R&D Day for analysts and investors at |
|
| April 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of inco |
|
| April 7, 2021 |
EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of April 07, 2021, is by and among RA Capital Management, L. |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TRILLIUM THERAPEUTICS INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) April 1, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| March 18, 2021 |
Description of the Registrant’s Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES Authorized Capital Our authorized share capital consists of an unlimited number of common shares, Class B shares and first preferred shares, in each case without nominal or par value. As of March 16, 2021, 103,032,563 common shares were issued and outstanding, no Class B shares were issued, no Series I Non-Voting Convertible First Preferred Sh |
|
| March 18, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 TRILLIUM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-36596 Not applicable (State or other jurisdiction of inco |
|
| March 18, 2021 |
Exhibit 10.15 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?), effective September 25, 2019 (?Effective Date?), is made between Trillium Therapeutics USA Inc., a Delaware corporation (?Employer? or the ?Company?), and Jan Skvarka (?Employee?). Employee and the Company are sometimes referred to herein as the ?Parties.? RECITALS A.??????????Employer is an immuno-oncology company in the |
|
| March 18, 2021 |
Exhibit 10.16 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (?Agreement?), effective November 2, 2020 (?Effective Date?), is made between Trillium Therapeutics USA Inc., a Delaware corporation (?Employer? or the ?Company?), and Ingmar Bruns, MD, PhD (?Employee?). Employee and the Company are sometimes referred to herein as the ?Parties? and individually as a ?Party.? RECITALS A.?????????Employer |
|
| March 18, 2021 |
TRILLIUM THERAPEUTICS REPORTS ANNUAL OPERATING AND FINANCIAL RESULTS AND SETS DATE FOR R&D DAY Exhibit 99.1 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS REPORTS ANNUAL OPERATING AND FINANCIAL RESULTS AND SETS DATE FOR R&D DAY · Wide-ranging transformation program completed · R&D Day Scheduled for April 28, 2021, to provide data updates, and announce strategic priorities and clinical development plan going forward · $291.2 million in cash, cash equivalents and marketabl |
|
| March 18, 2021 |
Exhibit 3.2 Mailing Address: Location: PO Box 9431 Stn Prov Govt 2nd Floor - 940 Blanshard Street Victoria BC V8W 9V3 Victoria BC www.corporateonline.gov.bc.ca 1 877 526-1526 Continuation Application CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies FORM 16 BUSINESS CORPORATIONS ACT CAROL PREST Section 302 CONTINUATION APPLICATION Name Reservation Numb |
|
| March 18, 2021 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Trillium Therapeutics USA Inc. Delaware |
|
| March 18, 2021 |
Form of Indemnification Agreement. Exhibit 10.19 INDEMNITY AGREEMENT THIS AGREEMENT is made as of this ? day of ?, ? BETWEEN: Trillium Therapeutics Inc., a corporation governed by the laws of the Province of British Columbia (the ?Corporation?) - and - ?, an individual principally resident in ?, in the Province of ? (the ?Indemnified Party?) RECITALS: A. The Indemnified Party is or has been a duly elected or appointed director and/ |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36596 TRILLIUM THERA |
|
| March 18, 2021 |
Indenture between Trillium Therapeutics Inc. and Penwest Revenue Corp., dated as of May 26, 2015. Exhibit 10.17 THIS INDENTURE made this 26th day of May, 2015. IN PURSUANCE OF THE SHORT FORMS OF LEASES ACT BETWEEN: PENWEST REVENUE CORP. herein called the ?Landlord? OF THE FIRST PART; - and - TRILLIUM THERAPEUTICS INC. herein called the ?Tenant? OF THE SECOND PART; W I T N E S S E T H T H A T: Article I DEFINITIONS 1.01 Definitions In this lease: i. ?Additional Rent? means all and any monies re |
|
| March 18, 2021 |
Exhibit 3.3 Number: C1234297 CERTIFICATE OF CONTINUATION BUSINESS CORPORATIONS ACT I Hereby Certify that Trillium Therapeutics Inc., has continued into British Columbia from the Jurisdiction of ONTARIO, under the Business Corporations Act, with the name TRILLIUM THERAPEUTICS INC. on December 18, 2019 at 09:58 AM Pacific Time. ELECTRONIC CERTIFICATE Issued under my hand at Victoria, British Columbi |
|
| March 18, 2021 |
Exhibit 10.18 January 3, 2019 PPF OFF 100 Cambridge Park Drive, LLC c/o Morgan Stanley Real Estate Advisor, Inc. 1585 Broadway, 37th Floor New York, New York 10036 Attention: Jennie Pries Friend VIA Courier Re: Trillium Therapeutics USA Inc. and PPF PFF 100 Cambridge Park Drive, LLC Lease Agreement Dear Ms. Friend, Please see attached two original copies of the lease agreement. Please sign and ret |
|
| March 18, 2021 |
Registration Statements (No. 333-254443) initially filed with the SEC on March 18, 2021 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 18, 2021 Registration No. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Trillium Therapeutics, Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 89620X506 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TRILLIUM THERAPEUTICS INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Trillium Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Trillium Therapeutics, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 12, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Trillium Therapeutics Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 89620X506 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| December 10, 2020 |
Registration No. 333-251262, initially filed with the SEC on December 10, 2020 As filed with the U.S. Securities and Exchange Commission on December 10, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRILLIUM THERAPEUTICS INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada Not Applicable (State or other jurisdiction of Incorpor |
|
| December 10, 2020 |
TRILLIUM THERAPEUTICS INC. 2020 OMNIBUS EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Trillium Therapeutics Inc. 2020 Omnibus Equity Incentive Plan (the "Plan"). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Trillium Therapeutics Inc., a company existing under the laws of |
|
| December 10, 2020 |
Trillium Therapeutics Inc. 2018 Amended and Restated Stock Option Plan TRILLIUM THERAPEUTICS INC. STOCK OPTION PLAN Amended and Restated as of March 8, 2018 1. Purpose of Plan The purpose of the Trillium Therapeutics Inc. (the ?Corporation?) Stock Option Plan (the ?Plan?) is to assist the Corporation in attracting, retaining and motivating directors, officers, consultants and employees of the Corporation and its subsidiaries and to closely align the personal interest |
|
| December 7, 2020 |
Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Du |
|
| December 7, 2020 |
FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS PRESENTED CLINICAL DATA AT THE 62ND ASH ANNUAL MEETING AND PROVIDES GUIDANCE FOR 2021 CAMBRIDGE, MA, December 7, 2020 - Trillium Therapeutics Inc. |
|
| November 25, 2020 |
FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS TO PRESENT CLINICAL DATA AT THE 62ND AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING CAMBRIDGE, MA, November 25, 2020 - Trillium Therapeutics Inc. |
|
| November 25, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of princip |
|
| November 16, 2020 |
TRILLIUM THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL AND OPERATING RESULTS FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS REPORTS THIRD QUARTER 2020 FINANCIAL AND OPERATING RESULTS CAMBRIDGE, MA, November 16, 2020 - Trillium Therapeutics Inc. |
|
| November 16, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, James Parsons, Chief Financial Officer of Trillium Therapeutics Inc. |
|
| November 16, 2020 |
EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019 Dated: November 11, 2020 2488 Dunwin Drive Mississauga, Ontario, L5L 1J9 www.trilliumtherapeutics.com TRILLIUM THERAPEUTICS INC. Management’s Discussion and Analysis ABOUT THIS MANAGEMENT'S DISCUSSION AND ANALYSIS All references in this management's discussion |
|
| November 16, 2020 |
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020 AND 2019 (UNAUDITED) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 www. |
|
| November 16, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of princip |
|
| November 16, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Jan Skvarka, Chief Executive Officer of Trillium Therapeutics Inc. |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of princip |
|
| November 12, 2020 |
FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS APPOINTS PAOLO PUCCI TO ITS BOARD OF DIRECTORS Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board CAMBRIDGE, MA, November 12, 2020 - Trillium Therapeutics Inc. |
|
| November 2, 2020 |
TRILLIUM THERAPEUTICS ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD CAMBRIDGE, MA, November 2, 2020 - Trillium Therapeutics Inc. |
|
| November 2, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of princip |
|
| November 2, 2020 |
TRILLIUM THERAPEUTICS APPOINTS DR. INGMAR BRUNS AS CHIEF MEDICAL OFFICER FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS APPOINTS DR. INGMAR BRUNS AS CHIEF MEDICAL OFFICER CAMBRIDGE, MA, November 2, 2020 - Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of Ingmar Bruns, M.D., Ph.D. as Chief |
|
| October 5, 2020 |
TRILLIUM THERAPEUTICS RECEIVES NOTICES OF ALLOWANCE FROM U.S. PATENT AND TRADEMARK OFFICE FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS RECEIVES NOTICES OF ALLOWANCE FROM U. |
|
| October 5, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of principa |
|
| September 18, 2020 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS APPOINTS MICHAEL KAMARCK, PH.D., TO ITS BOARD OF DIRECTORS Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board CAMBRIDGE, MA, September 18, 2020 - Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company |
|
| September 18, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of princi |
|
| September 16, 2020 |
Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 D |
|
| September 16, 2020 |
Trillium Closes US$150 Million Public Offering of Common Shares FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL Trillium Closes US$150 Million Public Offering of Common Shares CAMBRIDGE, MA, September 16, 2020 - Trillium Therapeutics Inc. |
|
| September 11, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-237810 PROSPECTUS SUPPLEMENT (To prospectus dated May 4, 2020) 10,000,000 Common Shares We are offering 10,000,000 common shares. Our common shares are listed on the Toronto Stock Exchange, or the TSX, and on the Nasdaq Capital Market, or the Nasdaq, under the symbol "TRIL". On September 9, 2020, the closing price of the common shares on the T |
|
| September 11, 2020 |
TRILLIUM ANNOUNCES PRICING OF US$130 MILLION PUBLIC OFFERING OF COMMON SHARES FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM ANNOUNCES PRICING OF US$130 MILLION PUBLIC OFFERING OF COMMON SHARES CAMBRIDGE, MA, September 10, 2020 - Trillium Therapeutics Inc. |
|
| September 11, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of princi |
|
| September 11, 2020 |
TRILLIUM THERAPEUTICS INC. 10,000,000 Common Shares UNDERWRITING AGREEMENT TRILLIUM THERAPEUTICS INC. 10,000,000 Common Shares UNDERWRITING AGREEMENT September 10, 2020 Cowen and Company, LLC Evercore Group L.L.C As Representatives of the several Underwriters Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Evercore Group L.L.C. 55 East 52nd Street New York, New York 10055 Ladies and Gentlemen: Trillium Therapeutics Inc., a corporation organized under |
|
| September 9, 2020 |
TRILLIUM THERAPEUTICS ANNOUNCES $25 MILLION EQUITY INVESTMENT FROM PFIZER INC. FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS ANNOUNCES $25 MILLION EQUITY INVESTMENT FROM PFIZER INC. |
|
| September 9, 2020 |
Subject to completion dated September 9, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-237810 The information in this preliminary prospectus supplement is not complete and may be changed. The registration statement filed with the Securities and Exchange Commission relating to these securities is effective. This preliminary prospectus supplement is not an offer to sell these securities and we are not soliciting offers to buy thes |
|
| September 9, 2020 |
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this "Agreement") is dated as of September 8, 2020, between Trillium Therapeutics Inc. |
|
| September 9, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of princi |
|
| September 9, 2020 |
TRILLIUM ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES CAMBRIDGE, MA, September 9, 2020 - Trillium Therapeutics Inc. |
|
| September 9, 2020 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-237810 PROSPECTUS SUPPLEMENT (To the prospectus dated May 4, 2020) 2,297,794 Common Shares We are offering 2,297,794 common shares directly to the investor in this offering at a price of US$10.88 per share. We are not paying underwriting discounts or commissions, so the proceeds to us, before expenses, will be approximately US$25.0 million. We |
|
| September 9, 2020 |
Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 D |
|
| September 8, 2020 |
FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS ANNOUNCES UPDATED DATA FROM ITS ONGOING TTI-622 AND TTI-621 DOSE ESCALATION STUDIES TTI-622 (SIRPα-IgG4 Fc) completed 8 mg/kg safety assessment in the ongoing dose escalation study in relapsed/refractory lymphoma; now escalating to 12 mg/kg dose level. |
|
| September 8, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of princi |
|
| August 12, 2020 |
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2020 AND 2019 (UNAUDITED) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 www. |
|
| August 12, 2020 |
TRILLIUM THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL AND OPERATING RESULTS FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL AND OPERATING RESULTS • TTI-621 study has progressed to the 2. |
|
| August 12, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, James Parsons, Chief Financial Officer of Trillium Therapeutics Inc. |
|
| August 12, 2020 |
Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunw |
|
| August 12, 2020 |
MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2020 AND 2019 Dated: August 11, 2020 2488 Dunwin Drive Mississauga, Ontario, L5L 1J9 www. |
|
| August 12, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Jan Skvarka, Chief Executive Officer of Trillium Therapeutics Inc. |
|
| July 30, 2020 |
FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS PROVIDES UPDATE ON PHASE 1 STUDY OF TTI-621 AND DOSE ESCALATION TO 2. |
|
| July 30, 2020 |
Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin |
|
| July 6, 2020 |
July 6, 2020 British Columbia Securities Commission Alberta Securities Commission The Manitoba Securities Commission Ontario Securities Commission Nova Scotia Securities Commission Via Sedar NOTICE PURSUANT TO SUBSECTION 11. |
|
| July 6, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of principal e |
|
| July 6, 2020 |
TRILLIUM ANNOUNCES VOTING RESULTS FROM THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS FOR IMMEDIATE RELEASE NASDAQ:TRIL TSX: TRIL TRILLIUM ANNOUNCES VOTING RESULTS FROM THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS CAMBRIDGE, MA, July 6, 2020 - Trillium Therapeutics Inc. |
|
| May 29, 2020 |
Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin |
|
| May 29, 2020 |
FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS PROVIDES UPDATE ON THE PHASE I DOSE ESCALATION STUDY OF ITS CD47 BLOCKER TTI-622 AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM Dosing has progressed through first five cohorts up to 4 mg/kg dose level Strong safety profile, with no dose-limiting toxicities observed Monotherapy activity (1 CR and 1 PR) observed in DLBCL patients Further dose escalation is underway, currently dosing at 8 mg/kg CAMBRIDGE, MA, May 29, 2020 - Trillium Therapeutics Inc. |
|
| May 26, 2020 |
PLEASE VIEW THE INFORMATION CIRCULAR PRIOR TO VOTING Have questions about this notice? Call the Toll Free Number below or scan the QR code to find out more Toll Free - 1-866 964-0492 www. |
|
| May 26, 2020 |
To: All Canadian Securities Regulatory Authorities 100 University Avenue, 8th floor Date: May 15, 2020 Toronto ON, M5J 2Y1 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: TRILLIUM THERAPEUTICS INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and Special Meeting Record Date for Notice of Meeting : May 15, 2 |
|
| May 26, 2020 |
Annual and Special Meeting of Shareholders Management Information Circular Annual and Special Meeting of Shareholders Management Information Circular This Management Information Circular (this "Circular") is furnished in connection with the solicitation of proxies by and on behalf of the management of Trillium Therapeutics Inc. |
|
| May 26, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of principal e |
|
| May 26, 2020 |
Proxies submitted must be received by 1:00 pm (Toronto time) on June 26, 2020. Security Class Holder Account Number - Fold Form of Proxy - Annual General and Special Meeting to be held on June 30, 2020 This Form of Proxy is solicited by and on behalf of Management. |
|
| May 15, 2020 |
TRILLIUM THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL AND OPERATING RESULTS FOR IMMEDIATE RELEASE NASDAQ:TRIL TSX: TRIL TRILLIUM THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL AND OPERATING RESULTS CAMBRIDGE, MA, May 15, 2020 - Trillium Therapeutics Inc. |
|
| May 15, 2020 |
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019 (UNAUDITED) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 www. |
|
| May 15, 2020 |
MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019 Dated: May 6, 2020 2488 Dunwin Drive Mississauga, Ontario, L5L 1J9 www. |
|
| May 15, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Jan Skvarka, Chief Executive Officer of Trillium Therapeutics Inc. |
|
| May 15, 2020 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, James Parsons, Chief Financial Officer of Trillium Therapeutics Inc. |
|
| May 15, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of principal e |
|
| May 13, 2020 |
Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin |
|
| May 13, 2020 |
FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS TO PRESENT DATA ON CD47 BLOCKER TTI-622 IN ADVANCED RELAPSED OR REFRACTORY LYMPHOMA AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM CAMBRIDGE, MA, May 13, 2020 - Trillium Therapeutics Inc. |
|
| May 6, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of principal e |
|
| May 6, 2020 |
TRILLIUM THERAPEUTICS ANNOUNCES "AT-THE-MARKET" EQUITY PROGRAM FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS ANNOUNCES "AT-THE-MARKET" EQUITY PROGRAM CAMBRIDGE, MA, May 6, 2020 - Trillium Therapeutics Inc. |
|
| May 5, 2020 |
Up to US$50,000,000 Common Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-237810 PROSPECTUS SUPPLEMENT (To prospectus dated May 4, 2020) Up to US$50,000,000 Common Shares We have entered into a sales agreement, or Sales Agreement, with Evercore Group L.L.C., or Evercore, dated May 5, 2020, relating to the sale of our common shares from time to time offered by this prospectus supplement and the accompanying prospect |
|
| May 5, 2020 |
Baker & McKenzie LLP Barristers & Solicitors Brookfield Place Bay/Wellington Tower 181 Bay Street, Suite 2100 Toronto, ON M5J 2T3 Canada Tel: +1 416 863 1221 Fax: +1 416 863 6275 www. |
|
| May 5, 2020 |
TRILLIUM THERAPEUTICS INC. US$50,000,000 Common Shares SALES AGREEMENT TRILLIUM THERAPEUTICS INC. US$50,000,000 Common Shares SALES AGREEMENT May 5, 2020 Evercore Group L.L.C 55 East 52nd Street New York, New York 10055 Ladies and Gentlemen: Trillium Therapeutics Inc., a corporation organized under the laws of the Province of British Columbia, Canada (the "Company"), confirms its agreement (this "Agreement") with Evercore Group L.L.C. ("Evercore"), as follows: 1. Iss |
|
| May 5, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of principal e |
|
| April 30, 2020 |
As filed with the Securities and Exchange Commission on April 30, 2020 Registration No. |
|
| April 30, 2020 |
Trillium Therapeutics Inc. 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada April 30, 2020 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Trillium Therapeutics Inc. - Registration Statement on Form F-3 filed April 23, 2020 (File No. 333-237810) as amended April 30, 2020 Ladies and Gentlemen: |
|
| April 23, 2020 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of principal |
|
| April 23, 2020 |
Registration Statement (No. 333-237810) initially filed with the SEC on April 23, 2020 As filed with the Securities and Exchange Commission on April 23, 2020 Registration No. |
|
| April 23, 2020 |
TRILLIUM THERAPEUTICS INC. Continuation Number: C1234297 (the "Company") 1 TRILLIUM THERAPEUTICS INC. Continuation Number: C1234297 (the "Company") ARTICLES 1. Interpretation 1 1.1 Definitions 1 1.2 Business Corporations Act and Interpretation Act Definitions Applicable 1 2. Shares and Share Certificates 1 2.1 Authorized Share Structure 1 2.2 Form of Share Certificate 1 2.3 Shareholder Entitled to Certificate or Acknowledgment 1 2.4 Delivery by Mail 2 2.5 Replacement o |
|
| April 8, 2020 |
TRILLIUM THERAPEUTICS PROVIDES BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS PROVIDES BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC First patients in the 1. |
|
| April 8, 2020 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of principal |
|
| March 10, 2020 |
Exhibit 99.6 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Trillium Therapeutics Inc. (the "Company") on Form 40-F for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jan Skvarka, President and Chief Executive |
|
| March 10, 2020 |
Management's Discussion and Analysis for the years ended December 31, 2019 and 2018 MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 Dated: March 5, 2020 2488 Dunwin Drive Mississauga, Ontario, L5L 1J9 www. |
|
| March 10, 2020 |
CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2019 AND 2018 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 www. |
|
| March 10, 2020 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, James Parsons, Chief Financial Officer of Trillium Therapeutics Inc. |
|
| March 10, 2020 |
Exhibit 99.4 CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED I, Jan Skvarka, certify that: 1. I have reviewed this annual report on Form 40-F of Trillium Therapeutics Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in |
|
| March 10, 2020 |
Exhibit 99.5 CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED I, James Parsons, certify that: 1. I have reviewed this annual report on Form 40-F of Trillium Therapeutics Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| March 10, 2020 |
Exhibit 99.7 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Trillium Therapeutics Inc. (the "Company") on Form 40-F for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James Parsons, Chief Financial Officer of t |
|
| March 10, 2020 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Jan Skvarka, Chief Executive Officer of Trillium Therapeutics Inc. |
|
| March 10, 2020 |
TRIL / Trillium Therapeutics Inc. 40-F - - FORM 40-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F (Check One) [ ] Registration statement pursuant to Section 12 of the Securities Exchange Act of 1934 or [X] Annual report pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 Commission file number 001-36596 TRILLIUM THERAPEUTICS INC. (Exact name of reg |
|
| March 10, 2020 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - CURRENT REPORT Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunw |
|
| March 10, 2020 |
TRILLIUM THERAPEUTICS REPORTS ANNUAL FINANCIAL AND OPERATING RESULTS FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS REPORTS ANNUAL FINANCIAL AND OPERATING RESULTS CAMBRIDGE, MA, March 10, 2020 - Trillium Therapeutics Inc. |
|
| March 10, 2020 |
Annual Information Form for the fiscal year ended December 31, 2019 ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2019 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 www. |
|
| March 10, 2020 |
Exhibit 99.8 Consent of Independent Registered Public Accounting Firm We consent to the reference to our Firm under the caption "Experts", and to the incorporation by reference in the following Registration Statements: 1. Form S-8 no. 333-234688 pertaining to the 2019 Inducement Stock Option Plan; 2. Form F-3 no. 333-224983 of Trillium Therapeutics Inc. and the use herein of our report dated March |
|
| February 28, 2020 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 D |
|
| February 28, 2020 |
TRILLIUM THERAPEUTICS RESPONDS TO MARKET ACTIVITY FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS RESPONDS TO MARKET ACTIVITY CAMBRIDGE, MA, February 28, 2020 - At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. |
|
| February 14, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Trillium Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 14, 2020 |
TRIL / Trillium Therapeutics Inc. / Sio Capital Management, LLC Passive Investment CUSIP No. 89620X506 Page 1 of 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Trillium Therapeutics Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 89620X506 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 7, 2020 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Trillium Therapeutics Inc. (the "Company" or "Trillium") 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Item 2. Date of Material Change January 29, 2020 Item 3. News Release The news release dated January 29, 2020 was disseminated through the services of Globe Newswire and was filed on the System for Electronic Document Analy |
|
| February 7, 2020 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 D |
|
| February 7, 2020 |
FORM 51-102F3 MATERIAL CHANGE REPORT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Trillium Therapeutics Inc. (the "Company" or "Trillium") 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Item 2. Date of Material Change February 6, 2020 Item 3. News Release The news release dated February 7, 2020 was disseminated through the services of Globe Newswire and was filed on the System for Electronic Document Analy |
|
| February 7, 2020 |
FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS • Paul Walker of New Enterprise Associates is appointed to the Board of Directors CAMBRIDGE, MA, February 7, 2020 - Trillium Therapeutics Inc. |
|
| February 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Trillium Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Add |
|
| February 3, 2020 |
TRIL / Trillium Therapeutics Inc. / Boxer Capital, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Trillium Therapeutics Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) January 23, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 3, 2020 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the common stock of Trillium Therapeutics Inc., no par value, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended |
|
| February 3, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, no par value, of Trillium Therapeutics, Inc., and further agree that this Joint Filing Agreement be incl |
|
| February 3, 2020 |
TRIL / Trillium Therapeutics Inc. / Vivo Capital IX, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Trillium Therapeutics, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) January 27, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 29, 2020 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - CURRENT REPORT Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Du |
|
| January 29, 2020 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares CAMBRIDGE, Mass., January 29, 2020 - Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for t |
|
| January 23, 2020 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE TSX: TRIL NASDAQ: TRIL TRILLIUM ANNOUNCES PRICING OF US$101,700,000 PUBLIC OFFERING OF COMMON SHARES AND SERIES II NON-VOTING CONVERTIBLE FIRST PREFERRED SHARES CAMBRIDGE, Mass., January 23, 2020 - Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative t |
|
| January 23, 2020 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - CURRENT REPORT Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Du |
|
| January 23, 2020 |
TRIL / Trillium Therapeutics Inc. SUPPL - - SUPPL Filed pursuant to General Instructions II.L. of Form F-10 File No. 333-222085 A copy of this preliminary prospectus supplement or this ''prospectus supplement'' has been filed with the securities regulatory authorities in each of the provinces of British Columbia, Alberta, Manitoba, Ontario and Nova Scotia but has not yet become final for the purpose of the sale of securities. Information containe |
|
| January 23, 2020 |
TRIL / Trillium Therapeutics Inc. SUPPL - - SUPPL Filed pursuant to General Instructions II.L. of Form F-10 File No. 333-222085 This prospectus supplement, together with the accompanying short form base shelf prospectus dated January 5, 2018 to which this prospectus supplement relates, as amended or supplemented, and each document deemed to be incorporated by reference into this prospectus supplement and the accompanying prospectus, constitutes a |
|
| January 23, 2020 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 TRILLIUM THERAPEUTICS INC. 35,731,818 Common Shares 1,250,000 Series II Non-Voting Convertible First Preferred Shares UNDERWRITING AGREEMENT January 23, 2020 COWEN AND COMPANY, LLC As Representative of the several Underwriters 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: Trillium Therapeutics Inc., a corporation organized under the laws |
|
| January 23, 2020 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Du |
|
| January 22, 2020 |
FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES AND SERIES II NON-VOTING CONVERTIBLE FIRST PREFERRED SHARES CAMBRIDGE, January 22, 2020 - Trillium Therapeutics Inc. |
|
| January 22, 2020 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Du |
|
| January 21, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Trillium Therapeutics Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 89620X506 (CUSIP Number) December 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 21, 2020 |
Exhibit 99.A EXHIBIT A JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Shares of Trillium Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such |
|
| January 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Trillium Therapeutics, Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 89620X506 (CUSIP Number) January 9, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| January 21, 2020 |
POWER OF ATTORNEY FOR BONG KOH Exhibit 99.C EXHIBIT C POWER OF ATTORNEY FOR BONG KOH KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to: (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are requi |
|
| January 21, 2020 |
POWER OF ATTORNEY FOR NIMISH SHAH Exhibit 99.B EXHIBIT B POWER OF ATTORNEY FOR NIMISH SHAH KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints each of David L. Stepp, Sherman G. Souther and Lisa D. Harris signing individually, the undersigned’s true and lawful attorney-in fact and agent to: (i) prepare execute and file, for and on behalf of the undersigned, any and all documents and filings that are re |
|
| January 16, 2020 |
TRILLIUM THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT CAMBRIDGE, MA, January 16, 2020 - Trillium Therapeutics Inc. |
|
| January 16, 2020 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Du |
|
| January 7, 2020 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2020 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Du |
|
| January 7, 2020 |
TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CD47 PROGRAMS EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS PROVIDES UPDATE ON ITS TTI-621 AND TTI-622 CD47 PROGRAMS Intravenous TTI-621 dose escalation under initial dose limiting toxicity (DLT) criteria now completed - confirms TTI-621 monotherapy activity (including complete responses) in hematologic malignancies at doses up to 0.5 mg/kg Further TTI |
|
| November 14, 2019 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Robert Kirkman, Executive Chairman of Trillium Therapeutics Inc. |
|
| November 14, 2019 |
Registration No. 333-234688, initially filed with the SEC on November 14, 2019 As filed with the Securities and Exchange Commission on November 14, 2019 Registration No. |
|
| November 14, 2019 |
MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018 Dated: November 7, 2019 2488 Dunwin Drive Mississauga, Ontario, L5L 1J9 www. |
|
| November 14, 2019 |
EX-99.1 4 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 TRILLIUM THERAPEUTICS INC. 2019 INDUCEMENT STOCK OPTION PLAN 1. Purpose of Plan The purpose of the Trillium Therapeutics Inc. (the “Corporation”) 2019 Inducement Stock Option Plan (the “Plan”) is to enable the Corporation to grant options (“Options”) to acquire common shares (“Common Shares”) in the capital of the Corporation to individuals who h |
|
| November 14, 2019 |
TRILLIUM THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE TORONTO, November 14, 2019 - Trillium Therapeutics Inc. |
|
| November 14, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada (Address of princip |
|
| November 14, 2019 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018 (UNAUDITED) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 www.trilliumtherapeutics.com TRILLIUM THERAPEUTICS INC. Interim Condensed Consolidated Statements of Financial Position Amounts in thousands of Canadian dollars (Unaudited) As at As at N |
|
| November 14, 2019 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, James Parsons, Chief Financial Officer of Trillium Therapeutics Inc. |
|
| November 6, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 D |
|
| November 6, 2019 |
FOR IMMEDIATE RELEASE NASDAQ:TRIL TSX: TRIL TRILLIUM THERAPEUTICS TO REPORT PRECLINICAL DATA ON ITS STING PROGRAM AT THE SITC 34TH ANNUAL MEETING TORONTO, November 6, 2019 - Trillium Therapeutics Inc. |
|
| October 22, 2019 |
TRILLIUM THERAPEUTICS ANNOUNCES CORPORATE RESTRUCTURING AND PROVIDES CD47 PROGRAM UPDATE EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE NASDAQ:TRIL TSX: TRIL TRILLIUM THERAPEUTICS ANNOUNCES CORPORATE RESTRUCTURING AND PROVIDES CD47 PROGRAM UPDATE TORONTO, October 22, 2019 - Trillium Therapeutics Inc. (Trillium, 'the company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced corporate |
|
| October 22, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - CURRENT REPORT Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Du |
|
| October 8, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - CURRENT REPORT Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Du |
|
| October 8, 2019 |
TRILLIUM GRANTED 180-DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH MINIMUM BID PRICE RULE EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE NASDAQ:TRIL TSX: TRIL TRILLIUM GRANTED 180-DAY EXTENSION BY NASDAQ TO REGAIN COMPLIANCE WITH MINIMUM BID PRICE RULE Toronto, October 8, 2019 - Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has received a notifica |
|
| September 25, 2019 |
FOR IMMEDIATE RELEASE NASDAQ:TRIL TSX: TRIL TRILLIUM THERAPEUTICS APPOINTS JAN SKVARKA AS PRESIDENT AND CHIEF EXECUTIVE OFFICER REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4) TORONTO, September 25, 2019 - Trillium Therapeutics Inc. |
|
| September 25, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 |
|
| September 5, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 |
|
| September 5, 2019 |
TRILLIUM THERAPEUTICS TO PRESENT AT INVESTOR CONFERENCE Trillium Therapeutics Inc. - Exhibit 99.1 - Filed by newsfilecorp.com FOR IMMEDIATE RELEASE NASDAQ:TRIL TSX: TRIL TRILLIUM THERAPEUTICS TO PRESENT AT INVESTOR CONFERENCE TORONTO, September 5, 2019 – Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to pre |
|
| August 13, 2019 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Trillium Therapeutics Inc. - Exhibit 99.3 - Filed by newsfilecorp.com FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Robert Kirkman, Executive Chairman of Trillium Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Trillium Therapeutics Inc. (the “issuer”) for the interim period |
|
| August 13, 2019 |
TRILLIUM THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS EX-99.5 6 exhibit99-5.htm EXHIBIT 99.5 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS TORONTO, August 13, 2019 – Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the six months ended June 30, 2019. |
|
| August 13, 2019 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND 2018 (UNAUDITED) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 www.trilliumtherapeutics.com TRILLIUM THERAPEUTICS INC. Interim Condensed Consolidated Statements of Financial Position Amounts in thousands of Canadian dollars (Unaudited) As at As at Note Ju |
|
| August 13, 2019 |
EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2019 AND 2018 Dated: August 12, 2019 2488 Dunwin Drive Mississauga, Ontario, L5L 1J9 www.trilliumtherapeutics.com TRILLIUM THERAPEUTICS INC. Management’s Discussion and Analysis ABOUT THIS MANAGEMENT’S DISCUSSION AND ANALYSIS All references in this management’s discussion and ana |
|
| August 13, 2019 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Trillium Therapeutics Inc. - Exhibit 99.4 - Filed by newsfilecorp.com FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, James Parsons, Chief Financial Officer of Trillium Therapeutics Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Trillium Therapeutics Inc. (the “issuer”) for the interim pe |
|
| August 13, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dun |
|
| July 24, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwi |
|
| July 24, 2019 |
TRILLIUM THERAPEUTICS PROVIDES CORPORATE UPDATE EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS PROVIDES CORPORATE UPDATE FDA meeting scheduled to discuss the pivotal path for intratumoral TTI-621 in CTCL Intravenous TTI-621 protocol amended to enable dosing beyond 0.5 mg/kg and first patient cohort enrolling Enrollment in the first Simon's 2-stage CTCL cohort in the TTI-621 intravenous |
|
| July 2, 2019 |
TRILLIUM ANNOUNCES VOTING RESULTS FROM THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 FOR IMMEDIATE RELEASE NASDAQ:TRIL TSX: TRIL TRILLIUM ANNOUNCES VOTING RESULTS FROM THE ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TORONTO, July 2, 2019 – Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special M |
|
| July 2, 2019 |
Trillium Therapeutics Inc. - Exhibit 99.1 - Filed by newsfilecorp.com July 2, 2019 British Columbia Securities Commission Alberta Securities Commission The Manitoba Securities Commission Ontario Securities Commission Nova Scotia Securities Commission Via Sedar NOTICE PURSUANT TO SUBSECTION 11.3 OF NATIONAL INSTRUMENT 51-102 (“NI 51-102”) CONTINUOUS DISCLOSURE OBLIGATIONS Pursuant to the requiremen |
|
| July 2, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwi |
|
| May 21, 2019 |
To: All Canadian Securities Regulatory Authorities EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Date: May 16, 2019 100 University Avenue, 8th floor Toronto ON, M5J 2Y1 www.computershare.com AMENDED To: All Canadian Securities Regulatory Authorities Subject: TRILLIUM THERAPEUTICS INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and Special Meetin |
|
| May 21, 2019 |
Trillium Therapeutics Inc. - Exhibit 99.4 - Filed by newsfilecorp.com |
|
| May 21, 2019 |
Annual and Special Meeting of Shareholders Management Information Circular Trillium Therapeutics Inc. - Exhibit 99.2 - Filed by newsfilecorp.com Annual and Special Meeting of Shareholders Management Information Circular This Management Information Circular (this “Circular”) is furnished in connection with the solicitation of proxies by and on behalf of the management of Trillium Therapeutics Inc. (the “Corporation”), for use at our Annual and Special Meeting of Sharehold |
|
| May 21, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K - Current Report of Foreign Issuer - FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwin |
|
| May 21, 2019 |
Notice of Availability of Proxy Material Trillium Therapeutics Inc. - Exhibit 99.3 - Filed by newsfilecorp.com |
|
| May 13, 2019 |
Trillium Therapeutics Inc. - Exhibit 99.1 - Filed by newsfilecorp.com INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2019 AND 2018 (UNAUDITED) 2488 Dunwin Drive Mississauga, Ontario L5L 1J9 www.trilliumtherapeutics.com TRILLIUM THERAPEUTICS INC. Interim Condensed Consolidated Statements of Financial Position Amounts in thousands of Canadian dollars (Unaudi |
|
| May 13, 2019 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, James Parsons, Chief Financial Officer of Trillium Therapeutics Inc. |
|
| May 13, 2019 |
TRILLIUM THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS TORONTO, May 13, 2019 - Trillium Therapeutics Inc. |
|
| May 13, 2019 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Robert Kirkman, Executive Chairman of Trillium Therapeutics Inc. |
|
| May 13, 2019 |
EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2019 AND 2018 Dated: May 10, 2019 2488 Dunwin Drive Mississauga, Ontario, L5L 1J9 www.trilliumtherapeutics.com TRILLIUM THERAPEUTICS INC. Management’s Discussion and Analysis ABOUT THIS MANAGEMENT’S DISCUSSION AND ANALYSIS All references in this management’s discussion and analysis, or |
|
| May 13, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K Current Report of Foreign Issuer FORM 6-K – Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwi |
|
| April 30, 2019 |
TRILLIUM ANNOUNCES MANAGEMENT AND BOARD CHANGES AND PROVIDES CORPORATE UPDATE FOR IMMEDIATE RELEASE NASDAQ: TRIL TSX: TRIL TRILLIUM ANNOUNCES MANAGEMENT AND BOARD CHANGES AND PROVIDES CORPORATE UPDATE TORONTO, April 30, 2019 - Trillium Therapeutics Inc. |
|
| April 30, 2019 |
TRIL / Trillium Therapeutics Inc. 6-K (Current Report of Foreign Issuer) FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwi |
|
| April 15, 2019 |
TRIL / Trillium Therapeutics Inc. FORM 6-K (Current Report of Foreign Issuer) Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2019 Commission File Number: 001-36596 TRILLIUM THERAPEUTICS INC. (Translation of registrant's name into English) 2488 Dunwi |
|
| April 15, 2019 |
FOR IMMEDIATE RELEASE NASDAQ:TRIL TSX: TRIL TRILLIUM THERAPEUTICS ANNOUNCES PUBLICATION HIGHLIGHTING ACTIVITY OF TTI-621 IN SÉZARY SYNDROME PATIENTS Toronto, April 15, 2019 - Trillium Therapeutics Inc. |
